EDITAS MEDICINE INC.

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

07 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

06 6 2022 16:30:00 提供 Nasdaq GlobeNewswire

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

18 5 2022 06:45:00 提供 Nasdaq GlobeNewswire

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

12 5 2022 16:30:00 提供 Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

04 5 2022 13:30:00 提供 Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2022 Results and Business Updates

04 5 2022 06:45:00 提供 Nasdaq GlobeNewswire

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

02 5 2022 16:31:07 提供 Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

27 4 2022 06:55:00 提供 Nasdaq GlobeNewswire

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

26 4 2022 09:00:03 提供 Nasdaq GlobeNewswire

Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer

14 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

11 4 2022 09:00:00 提供 Nasdaq GlobeNewswire

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

08 4 2022 13:00:00 提供 Nasdaq GlobeNewswire

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

28 2 2022 16:01:00 提供 Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

24 2 2022 06:30:00 提供 Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

16 2 2022 06:15:00 提供 Nasdaq GlobeNewswire

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

10 1 2022 07:00:02 提供 Nasdaq GlobeNewswire

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 1 2022 06:58:00 提供 Nasdaq GlobeNewswire

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

20 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

12 12 2021 18:00:00 提供 Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

12 11 2021 07:00:02 提供 Nasdaq GlobeNewswire